778% Multibagger! Fredun Pharmaceuticals Near Record High After Strong Q1 FY27 Results

Fredun Pharmaceuticals Extends Rally After Strong Q1 FY27 Earnings

Fredun Pharmaceuticals continued its strong upward momentum after reporting an impressive set of financial results for the June quarter (Q1 FY27). The stock gained more than 3% during Friday's trading session and traded close to its all-time high, reflecting strong investor confidence following the earnings announcement.

The company has also emerged as one of the standout multibagger pharma stocks, delivering exceptional long-term returns.

Q1 FY27 Financial Highlights

Fredun Pharmaceuticals reported strong year-on-year growth across key financial metrics.

Revenue from Operations: ₹227.75 Crore (+90.7% YoY)

Net Profit (PAT): ₹13.13 Crore (+94.1% YoY)

Profit Before Tax (PBT): ₹20.55 Crore (+127.3% YoY)

The strong earnings growth highlights improved operational performance and continued business expansion.

Expenses Also Increased

Alongside higher revenue, the company reported an increase in operating expenses.

Major contributors included

• Raw material costs increased by 97.6%
• Depreciation expenses rose 151.6%
• Other operating expenses increased 52.5%

Despite higher costs, profitability improved significantly due to strong revenue growth.

Bonus Share Update

During the quarter, Fredun Pharmaceuticals completed the allotment of bonus shares in a 2:1 ratio.

This increased the company's paid-up equity share capital from approximately 55.13 lakh shares to 1.65 crore shares, improving liquidity in the stock.

Management Commentary

According to the company's management, the strong quarterly performance reflects the benefits of long-term investments and strategic expansion initiatives.

The company continues to focus on

• Expanding its branded healthcare portfolio
• Entering new healthcare segments
• Strengthening manufacturing capabilities
• Delivering sustainable long-term shareholder value

Share Price Performance

Fredun Pharmaceuticals has delivered exceptional returns across multiple timeframes.

1 Week: +24.62%

1 Month: +42.64%

3 Months: +56.23%

6 Months: +124.13%

2026 (YTD): +140.44%

1 Year: +242.65%

2 Years: +359.08%

3 Years: +252.10%

5 Years: +768.52%

The stock also traded near its lifetime high after the latest earnings announcement.

What's Driving the Rally?

Several factors have supported the recent rally in Fredun Pharmaceuticals

• Strong Q1 FY27 earnings growth
• Nearly doubled net profit
• Revenue growth of over 90%
• Positive management outlook
• Expansion into new healthcare segments
• Improved investor confidence in the pharmaceutical sector

Key Takeaways

• Fredun Pharmaceuticals reported strong Q1 FY27 financial performance.
• Revenue increased 90.7% YoY to ₹227.75 crore.
• Net profit almost doubled to ₹13.13 crore.
• The company completed a 2:1 bonus share issue during the quarter.
• The stock has generated an impressive 768% return over the past five years.
• Shares are currently trading close to their all-time high.

Disclaimer

This article is published solely for educational and informational purposes and should not be considered financial, investment, legal, or tax advice. The information presented is based on publicly available sources and is believed to be accurate at the time of publication; however, TrendRipperX does not guarantee its completeness or accuracy.

TrendRipperX is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst. Any views expressed are for informational purposes only and do not constitute a recommendation to buy, sell, or hold any security.

Investments in financial markets are subject to market risks. Readers should conduct their own research and consult a SEBI-registered financial advisor before making any investment decisions.